glp 1 menu A Simple 7-Day Meal Plan for People Taking a GLP-1 Default

The LEADER trial demonstrated a 13% reduction in MACE with liraglutide in high-risk patients with T2D

Jungnik, A

1- Visceral Fat Reduction (~1518%) Clinical studies have demonstrated that tesamorelin significantly reduces visceral adipose tissue (VAT) in individuals with HIV-associated lipodystrophy 2

For context on how injectable versus oral delivery compares across peptide and antioxidant compounds, this deep dive on BPC-157 orals versus injectables will give you the framework for thinking about these tradeoffs correctly

secondary IR cross-reactivity Key downstream pathways / PI3K-Akt-mTOR and RAS-MAPK-ERK IGF-1 DES comparison / DES is 6-aa truncated, 10x higher potency but even shorter half-life (~20-30 min) Regulatory status / Not FDA-approved for any indication